‘Deleted’ DNA Data Just Reappeared on a Popular Database
By Emily Mullin,
Future Human
| 01. 21. 2021
Over the past few years, the online DNA database GEDmatch has become a powerful tool for solving cold cases. Founded in 2010 to help adoptees and genealogy enthusiasts find biological relatives, the site shot to prominence in 2018 after California police said GEDmatch led them to a suspect in the decades-old Golden State Killer case.
The open-source database allows anyone to upload their raw DNA file generated from genetic testing firms like 23andMe and Ancestry. Then, they can search for other users who share their DNA. Police use the site to upload DNA found at crime scenes, look for matching relatives, then do traditional genealogy to zero in on a suspect. The database contains around 1.5 million DNA profiles uploaded by 1.1 million users. A recent technical glitch, however, threatens to undermine users’ trust in the site.
On January 14, a technical snafu at GEDmatch caused previously deleted user data to be restored for two days. It’s the second security incident the database has experienced in less than a year. In July 2020, hackers accessed the database and exposed...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...